HiFiBiO Therapeutics, a Cambridge, Massachusetts-based multinational biotechnology company with expertise in immune modulation and drug intelligent science, closed a $75M Series D financing round.
The round was led by the new investor Mirae Asset Financial Group with participation from Further, B Capital Group, Sherpa, Maison Capital, Trinity Innovation Fund, Grand Mount, and HKSTP Venture Fund and existing shareholders IDG, Sequoia, Legend Star, and Hengxu. With the new round, Ryan Jeong from Mirae Asset Capital will be joining the company’s Board of Directors.
The company intends to use the funds to advance two lead antibody oncology assets into Phase I clinical trials – HFB200301, a novel anti-TNFR2 antibody and HFB301001, a differentiated second generation anti-OX-40 antibody.
Led by Liang Schweizer, PhD, President and CEO, HiFiBiO Therapeutics is a multinational biotherapeutics company mobilizing the human immune system to combat disease. The company integrates deep-rooted biological expertise with its comprehensive single-cell profiling technologies to discover and accelerate a pipeline of antibody drugs to treat cancer and autoimmune disorders. The company has laboratories in three continents in Cambridge, Mass., Paris, France, Shanghai, Hong Kong, and Hangzhou in China.